Metastasis-Free Survival Endpoint Spreads To Labeling With US FDA Approval Of J&J's Erleada

Apalutamide, the first drug approved to treat non-metastatic castration-resistant prostate cancer, will also be the first NDA to have clinical summary report information made public under an FDA pilot program to increase transparency.